Branched-chain Amino Acids Supplementation and Resistance Exercise-induced Muscle Damage and Inflammation

Inflammation Clinical Trial

Official title:

Effects of Leucine and Branched-chain Amino Acids (BCAA) Supplementation on Resistance Exercise-induced Muscle Damage and Inflammation: a Randomized, Double-blind, and Placebo-controlled Study

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT01305018
• Other study ID #: 071287
• Status: Suspended
• Phase: N/A
• First received: February 25, 2011
• Last updated: May 4, 2011
• Start date: August 2011
• Est. completion date: August 2012

Study information

• Verified date: April 2011
• Source: University of Sao Paulo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the effects of branched-chain amino acids (BCAA) supplementation on resistance exercise-induced muscle damage and inflammation.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 30
• Est. completion date: August 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Sedentary;

• No muscle disorders;

• Must be able to swallow tablets

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Inflammation
• Muscle Damage

Intervention

Dietary Supplement:
• BCAA
7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
• Leucine
7 g of leucine + 7 g of alanine per day during 9 days
• Placebo
14 g of alanine per day during 9 days

Locations

Country	Name	City	State
Brazil	University of São Paulo - School of Physical Education and Sports	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
University of Sao Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscle maximal strength		4 days	Yes
Primary	Muscle edema		4 days	Yes
Primary	Muscle soreness		4 days	Yes
Secondary	Muscle inflammation	Immunohistochemistry, protein expression.	4 days	Yes
Secondary	Muscle damage	Serum creatine kinase	4 days	Yes